RT Journal Article
SR Electronic
T1 Predictors of Postviral Symptoms Following Epstein-Barr Virus-Associated Infectious Mononucleosis in Young People – Data from the IMMUC Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.17.24307333
DO 10.1101/2024.05.17.24307333
A1 Bodenhausen, Maren
A1 Geisperger, Jonas
A1 Lange de Luna, Julia
A1 Wendl, Johannes
A1 Hapfelmeier, Alexander
A1 Schulte-Hillen, Lina
A1 Pricoco, Rafael
A1 Körber, Nina
A1 Bauer, Tanja
A1 Mautner, Josef
A1 Hoffmann, Dieter
A1 Luppa, Peter
A1 Egert-Schwender, Silvia
A1 Nößner, Elfriede
A1 Delecluse, Henri-Jacques
A1 Delecluse, Susanne
A1 Hauck, Fabian
A1 Falk, Christine
A1 Schulz, Thomas
A1 Steinborn, Marc-Matthias
A1 Bietenbeck, Andreas
A1 Nieters, Alexandra
A1 Mihatsch, Lorenz
A1 Gerrer, Katrin
A1 Behrends, Uta
A1 the IMMUC Study Group
YR 2024
UL http://medrxiv.org/content/early/2024/05/17/2024.05.17.24307333.abstract
AB Background Epstein-Barr virus-associated Infectious Mononucleosis (EBV-IM) is a common disease following primary EBV infection in children and adolescents. While EBV-IM is mostly self-limiting, symptoms like fatigue may persist over several months or even result in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This large clinical observational study aimed at identifying risk factors for protracted courses of EBV-IM in young people.Methods A cohort of N=200 children, adolescents, and young adults with acute primary EBV infection was recruited from hospitals and private practices. Data on the patients’ medical history as well as clinical and laboratory parameters were collected at a baseline visit (V1) within four weeks after symptom onset (Tonset) and at two follow-up visits (V2 and V3) one and six months after Tonset. Risk factors for protracted symptoms at V3 were modeled using multivariable logistic regressions.Results Protracted symptoms were observed in 55/183 (30.1%) and protracted fatigue in 34/181 (18.8%) patients at V3. A medical history indicating an increased susceptibility to infectious diseases as well as distinct severe IM symptoms, e.g. severe gastrointestinal symptoms, were significantly associated with protracted disease [OR: 2.31; P=0.011 and OR: 3.42; P=0.027] and with chronic fatigue [OR: 2.98; P=0.006 and OR: 3.54; P=0.034], respectively. Occurrence of twelve or more clinical and laboratory parameters until and including V1 discriminated between fatigue and no fatigue at V3 [OR 2.43, P=0.033].Conclusion A clinical history of immune dysregulation as well as distinct severe IM symptoms might predict protracted post-viral disease and thus help in the identification of young patients at risk.HighlightsSevere gastrointestinal symptoms are associated with protracted course of Epstein-Barr virus-associated Infectious Mononucleosis (EBV-IM).Signs of immune dysregulation prior to EBV-IM can indicate an increased risk of protracted symptoms.Greater number of initial symptoms helps to identify patients developing postviral fatigue.Competing Interest StatementA.B. received lecture fees from Siemens. U.B. received research grants for ME/CFS or EBV studies from the Federal Ministry of Education and Research, the Federal Ministry of Health, the Bavarian State Ministry of Health and Care, the Bavarian State Ministry of Science and the Arts, the German Center for Infection Research, the People for Children (Menschen fuer Kinder) foundation, the Weidenhammer-Zoebele Foundation, the Lost Voices Foundation, and the ME/CFS research foundation. All other authors have no conflict of interest to declare.Funding StatementThe German Center for Infection Research (DZIF) (grant numbers 07_905 and 07_909). Funding was acquired by U.B. and received by P.L., S.E-S., A.H., D.H., F.H., J.M., T.B., H-J.D., C.F., and T.S..Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the TUM School of Medicine and Health of the Technical University of Munich in Germany gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study is not openly available.